Skip to main content
Top
Published in: BMC Health Services Research 1/2024

Open Access 01-12-2024 | Pancreatic Cancer | Research

Simulating the healthcare workforce impact and capacity for pancreatic cancer care in Victoria: a model-based analysis

Authors: Lan Gao, Anna Ugalde, Patricia M Livingston, Victoria White, Jennifer J Watts, Hannah Jongebloed, Nikki McCaffrey, David Menzies, Suzanne Robinson

Published in: BMC Health Services Research | Issue 1/2024

Login to get access

Abstract

Background

The incidence of pancreatic cancer is rising. With improvements in knowledge for screening and early detection, earlier detection of pancreatic cancer will continue to be more common. To support workforce planning, our aim is to perform a model-based analysis that simulates the potential impact on the healthcare workforce, assuming an earlier diagnosis of pancreatic cancer.

Methods

We developed a simulation model to estimate the demand (i.e. new cases of pancreatic cancer) and supply (i.e. the healthcare workforce including general surgeons, medical oncologists, radiation oncologists, pain medicine physicians, and palliative care physicians) between 2023 and 2027 in Victoria, Australia. The model compares the current scenario to one in which pancreatic cancer is diagnosed at an earlier stage. The incidence of pancreatic cancer in Victoria, five-year survival rates, and Victoria’s population size were obtained from Victorian Cancer Registry, Cancer Council NSW, and Australian Bureau of Statistics respectively. The healthcare workforce data were sourced from the Australian Government Department of Health and Aged Care’s Health Workforce Data. The model was constructed at the remoteness level. We analysed the new cases and the number of healthcare workforce by profession together to assess the impact on the healthcare workforce.

Results

In the status quo, over the next five years, there will be 198 to 220 stages I-II, 297 to 330 stage III, and 495 to 550 stage IV pancreatic cancer cases diagnosed annually, respectively. Assuming 20–70% of the shift towards pancreatic cancer’s earlier diagnosis (shifting from stage IV to stages I-II pancreatic cancer within one year), the stages I-II cases could increase to 351 to 390 or 598 to 665 per year. The shift to early diagnosis led to substantial survival gains, translating into an additional 284 or 795 out of 5246 patients with pancreatic cancer remaining alive up to year 5 post-diagnosis. Workforce supply decreases significantly by the remoteness levels, and remote areas face a shortage of key medical professionals registered in delivering pancreatic cancer care, suggesting travel necessities by patients or clinicians.

Conclusion

Improving the early detection and diagnosis of pancreatic cancer is expected to bring significant survival benefits, although there are workforce distribution imbalances in Victoria that may affect the ability to achieve the anticipated survival gain.
Appendix
Available only for authorised users
Literature
1.
go back to reference Pourshams A, Sepanlou SG, Ikuta KS, Bisignano C, Safiri S, Roshandel G, et al. The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the global burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2019;4(12):934–47.CrossRef Pourshams A, Sepanlou SG, Ikuta KS, Bisignano C, Safiri S, Roshandel G, et al. The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the global burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2019;4(12):934–47.CrossRef
2.
go back to reference Australian Institute of Health and Welfare. Cancer in Australia 2021. Cancer series no. 133. Cat. No. CAN 144. Canberra: AIHW; 2021. Australian Institute of Health and Welfare. Cancer in Australia 2021. Cancer series no. 133. Cat. No. CAN 144. Canberra: AIHW; 2021.
3.
go back to reference Jointly issued by the American Cancer Society (ACS). tCfDCaPC, the North American Association of Central Cancer Registries (NAACCR), and the National Cancer Institute (NCI),. Annual Report to the Nation on the Status of Cancer. Jointly issued by the American Cancer Society (ACS). tCfDCaPC, the North American Association of Central Cancer Registries (NAACCR), and the National Cancer Institute (NCI),. Annual Report to the Nation on the Status of Cancer.
5.
go back to reference Hendrick RE. Radiation doses and cancer risks from breast imaging studies. Radiology. 2010;257(1):246–53.PubMedCrossRef Hendrick RE. Radiation doses and cancer risks from breast imaging studies. Radiology. 2010;257(1):246–53.PubMedCrossRef
7.
go back to reference Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, Caughey AB, et al. Screening for pancreatic Cancer: US Preventive Services Task Force Reaffirmation Recommendation Statement. JAMA. 2019;322(5):438–44.PubMedCrossRef Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, Caughey AB, et al. Screening for pancreatic Cancer: US Preventive Services Task Force Reaffirmation Recommendation Statement. JAMA. 2019;322(5):438–44.PubMedCrossRef
8.
go back to reference Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.PubMedCrossRef Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.PubMedCrossRef
9.
go back to reference Force USPST, Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, et al. Screening for pancreatic Cancer: US Preventive Services Task Force Reaffirmation Recommendation Statement. JAMA. 2019;322(5):438–44.CrossRef Force USPST, Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, et al. Screening for pancreatic Cancer: US Preventive Services Task Force Reaffirmation Recommendation Statement. JAMA. 2019;322(5):438–44.CrossRef
10.
go back to reference Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74(11):2913–21.PubMedCrossRef Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74(11):2913–21.PubMedCrossRef
11.
go back to reference Canto MI, Harinck F, Hruban RH, Offerhaus GJ, Poley JW, Kamel I, et al. International Cancer of the pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut. 2013;62(3):339–47.PubMedCrossRef Canto MI, Harinck F, Hruban RH, Offerhaus GJ, Poley JW, Kamel I, et al. International Cancer of the pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut. 2013;62(3):339–47.PubMedCrossRef
12.
go back to reference Andersen DK, Korc M, Petersen GM, Eibl G, Li D, Rickels MR, et al. Diabetes, pancreatogenic diabetes, and pancreatic Cancer. Diabetes. 2017;66(5):1103–10.PubMedPubMedCentralCrossRef Andersen DK, Korc M, Petersen GM, Eibl G, Li D, Rickels MR, et al. Diabetes, pancreatogenic diabetes, and pancreatic Cancer. Diabetes. 2017;66(5):1103–10.PubMedPubMedCentralCrossRef
13.
go back to reference Cho J, Scragg R, Petrov MS. Postpancreatitis Diabetes confers higher risk for pancreatic Cancer Than Type 2 diabetes: results from a Nationwide Cancer Registry. Diabetes Care. 2020;43(9):2106–12.PubMedCrossRef Cho J, Scragg R, Petrov MS. Postpancreatitis Diabetes confers higher risk for pancreatic Cancer Than Type 2 diabetes: results from a Nationwide Cancer Registry. Diabetes Care. 2020;43(9):2106–12.PubMedCrossRef
14.
go back to reference Vege SS, Ziring B, Jain R, Moayyedi P, Clinical Guidelines C, American Gastroenterology A. American gastroenterological association institute guideline on the diagnosis and management of asymptomatic neoplastic pancreatic cysts. Gastroenterology. 2015;148(4):819–22. quize12-3.PubMedCrossRef Vege SS, Ziring B, Jain R, Moayyedi P, Clinical Guidelines C, American Gastroenterology A. American gastroenterological association institute guideline on the diagnosis and management of asymptomatic neoplastic pancreatic cysts. Gastroenterology. 2015;148(4):819–22. quize12-3.PubMedCrossRef
15.
go back to reference Del Chiaro M, Verbeke C, Salvia R, Kloppel G, Werner J, McKay C, et al. European experts consensus statement on cystic tumours of the pancreas. Dig Liver Dis. 2013;45(9):703–11.PubMedCrossRef Del Chiaro M, Verbeke C, Salvia R, Kloppel G, Werner J, McKay C, et al. European experts consensus statement on cystic tumours of the pancreas. Dig Liver Dis. 2013;45(9):703–11.PubMedCrossRef
16.
go back to reference Yadav D, Lowenfels AB. The epidemiology of pancreatitis and pancreatic cancer. Gastroenterology. 2013;144(6):1252–61.PubMedCrossRef Yadav D, Lowenfels AB. The epidemiology of pancreatitis and pancreatic cancer. Gastroenterology. 2013;144(6):1252–61.PubMedCrossRef
17.
go back to reference Arnold LD, Patel AV, Yan Y, Jacobs EJ, Thun MJ, Calle EE, et al. Are racial disparities in pancreatic cancer explained by smoking and overweight/obesity? Cancer Epidemiol Biomarkers Prev. 2009;18(9):2397–405.PubMedPubMedCentralCrossRef Arnold LD, Patel AV, Yan Y, Jacobs EJ, Thun MJ, Calle EE, et al. Are racial disparities in pancreatic cancer explained by smoking and overweight/obesity? Cancer Epidemiol Biomarkers Prev. 2009;18(9):2397–405.PubMedPubMedCentralCrossRef
18.
go back to reference Iodice S, Gandini S, Maisonneuve P, Lowenfels AB. Tobacco and the risk of pancreatic cancer: a review and meta-analysis. Langenbecks Arch Surg. 2008;393(4):535–45.PubMedCrossRef Iodice S, Gandini S, Maisonneuve P, Lowenfels AB. Tobacco and the risk of pancreatic cancer: a review and meta-analysis. Langenbecks Arch Surg. 2008;393(4):535–45.PubMedCrossRef
19.
go back to reference Tramacere I, Scotti L, Jenab M, Bagnardi V, Bellocco R, Rota M, et al. Alcohol drinking and pancreatic cancer risk: a meta-analysis of the dose-risk relation. Int J Cancer. 2010;126(6):1474–86.PubMedCrossRef Tramacere I, Scotti L, Jenab M, Bagnardi V, Bellocco R, Rota M, et al. Alcohol drinking and pancreatic cancer risk: a meta-analysis of the dose-risk relation. Int J Cancer. 2010;126(6):1474–86.PubMedCrossRef
20.
go back to reference Ben Q, Xu M, Ning X, Liu J, Hong S, Huang W, et al. Diabetes mellitus and risk of pancreatic cancer: a meta-analysis of cohort studies. Eur J Cancer. 2011;47(13):1928–37.PubMedCrossRef Ben Q, Xu M, Ning X, Liu J, Hong S, Huang W, et al. Diabetes mellitus and risk of pancreatic cancer: a meta-analysis of cohort studies. Eur J Cancer. 2011;47(13):1928–37.PubMedCrossRef
21.
go back to reference Malka D, Hammel P, Maire F, Rufat P, Madeira I, Pessione F, et al. Risk of pancreatic adenocarcinoma in chronic pancreatitis. Gut. 2002;51(6):849–52.PubMedPubMedCentralCrossRef Malka D, Hammel P, Maire F, Rufat P, Madeira I, Pessione F, et al. Risk of pancreatic adenocarcinoma in chronic pancreatitis. Gut. 2002;51(6):849–52.PubMedPubMedCentralCrossRef
22.
go back to reference Klein AP, Brune KA, Petersen GM, Goggins M, Tersmette AC, Offerhaus GJ, et al. Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res. 2004;64(7):2634–8.PubMedCrossRef Klein AP, Brune KA, Petersen GM, Goggins M, Tersmette AC, Offerhaus GJ, et al. Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res. 2004;64(7):2634–8.PubMedCrossRef
23.
go back to reference Santos R, Coleman HG, Cairnduff V, Kunzmann AT. Clinical prediction models for pancreatic Cancer in General and At-Risk populations: a systematic review. Am J Gastroenterol. 2023;118(1):26–40.PubMedCrossRef Santos R, Coleman HG, Cairnduff V, Kunzmann AT. Clinical prediction models for pancreatic Cancer in General and At-Risk populations: a systematic review. Am J Gastroenterol. 2023;118(1):26–40.PubMedCrossRef
24.
25.
go back to reference Hippisley-Cox J, Coupland C. Development and validation of risk prediction algorithms to estimate future risk of common cancers in men and women: prospective cohort study. BMJ Open. 2015;5(3):e007825.PubMedPubMedCentralCrossRef Hippisley-Cox J, Coupland C. Development and validation of risk prediction algorithms to estimate future risk of common cancers in men and women: prospective cohort study. BMJ Open. 2015;5(3):e007825.PubMedPubMedCentralCrossRef
27.
go back to reference Vasen H, Ibrahim I, Ponce CG, Slater EP, Matthai E, Carrato A, et al. Benefit of Surveillance for Pancreatic Cancer in High-Risk individuals: outcome of long-term prospective Follow-Up studies from three European Expert centers. J Clin Oncol. 2016;34(17):2010–9.PubMedCrossRef Vasen H, Ibrahim I, Ponce CG, Slater EP, Matthai E, Carrato A, et al. Benefit of Surveillance for Pancreatic Cancer in High-Risk individuals: outcome of long-term prospective Follow-Up studies from three European Expert centers. J Clin Oncol. 2016;34(17):2010–9.PubMedCrossRef
28.
go back to reference Wood LD, Canto MI, Jaffee EM, Simeone DM. Pancreatic Cancer: Pathogenesis, screening, diagnosis, and treatment. Gastroenterology. 2022;163(2):386–402. e1.PubMedCrossRef Wood LD, Canto MI, Jaffee EM, Simeone DM. Pancreatic Cancer: Pathogenesis, screening, diagnosis, and treatment. Gastroenterology. 2022;163(2):386–402. e1.PubMedCrossRef
29.
go back to reference Canto MI, Almario JA, Schulick RD, Yeo CJ, Klein A, Blackford A, et al. Risk of neoplastic progression in individuals at high risk for pancreatic Cancer Undergoing Long-Term Surveillance. Gastroenterology. 2018;155(3):740–.PubMedCrossRef Canto MI, Almario JA, Schulick RD, Yeo CJ, Klein A, Blackford A, et al. Risk of neoplastic progression in individuals at high risk for pancreatic Cancer Undergoing Long-Term Surveillance. Gastroenterology. 2018;155(3):740–.PubMedCrossRef
30.
go back to reference Overbeek KA, Levink IJM, Koopmann BDM, Harinck F, Konings I, Ausems M, et al. Long-term yield of pancreatic cancer surveillance in high-risk individuals. Gut. 2022;71(6):1152–60.PubMedCrossRef Overbeek KA, Levink IJM, Koopmann BDM, Harinck F, Konings I, Ausems M, et al. Long-term yield of pancreatic cancer surveillance in high-risk individuals. Gut. 2022;71(6):1152–60.PubMedCrossRef
31.
go back to reference Overbeek KA, Goggins MG, Dbouk M, Levink IJM, Koopmann BDM, Chuidian M, et al. Timeline of Development of Pancreatic Cancer and implications for successful early detection in high-risk individuals. Gastroenterology. 2022;162(3):772–85. e4.PubMedCrossRef Overbeek KA, Goggins MG, Dbouk M, Levink IJM, Koopmann BDM, Chuidian M, et al. Timeline of Development of Pancreatic Cancer and implications for successful early detection in high-risk individuals. Gastroenterology. 2022;162(3):772–85. e4.PubMedCrossRef
32.
go back to reference Segal L, Bolton T. Issues facing the future health care workforce: the importance of demand modelling. Aust New Z Health Policy. 2009;6:12.CrossRef Segal L, Bolton T. Issues facing the future health care workforce: the importance of demand modelling. Aust New Z Health Policy. 2009;6:12.CrossRef
33.
go back to reference Campbell J, Buchan J, Cometto G, David B, Dussault G, Fogstad H, et al. Human resources for health and universal health coverage: fostering equity and effective coverage. Bull World Health Organ. 2013;91(11):853–63.PubMedPubMedCentralCrossRef Campbell J, Buchan J, Cometto G, David B, Dussault G, Fogstad H, et al. Human resources for health and universal health coverage: fostering equity and effective coverage. Bull World Health Organ. 2013;91(11):853–63.PubMedPubMedCentralCrossRef
35.
go back to reference Victorian Cancer Registry. (2022). Pancreatic cancer (ICD-10: C25) incidence in Victoria 1982–2021. Victorian Cancer Registry. (2022). Pancreatic cancer (ICD-10: C25) incidence in Victoria 1982–2021.
38.
go back to reference Yu J, Blackford AL, Dal Molin M, Wolfgang CL, Goggins M. Time to progression of pancreatic ductal adenocarcinoma from low-to-high tumour stages. Gut. 2015;64(11):1783–9.PubMedCrossRef Yu J, Blackford AL, Dal Molin M, Wolfgang CL, Goggins M. Time to progression of pancreatic ductal adenocarcinoma from low-to-high tumour stages. Gut. 2015;64(11):1783–9.PubMedCrossRef
39.
go back to reference Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature. 2010;467(7319):1114–7.ADSPubMedPubMedCentralCrossRef Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature. 2010;467(7319):1114–7.ADSPubMedPubMedCentralCrossRef
43.
go back to reference Loveday BPT, Lipton L, Thomson BN. Pancreatic cancer: an update on diagnosis and management. Aust J Gen Pract. 2019;48(12):826–31.PubMedCrossRef Loveday BPT, Lipton L, Thomson BN. Pancreatic cancer: an update on diagnosis and management. Aust J Gen Pract. 2019;48(12):826–31.PubMedCrossRef
44.
go back to reference Australian Government Labour Market Information Portal., Health Care and Social Assistance, viewed July 2019. Australian Government Labour Market Information Portal., Health Care and Social Assistance, viewed July 2019.
45.
go back to reference World Health Organization. Global Health Workforce Alliance. Human resources for health: foundation for universal health coverage and the post2015 development agenda. Report of the Third Global Forum on Human Resources for Health., 2013 November 10–13. Recife, Brazil: WHO; 2014. World Health Organization. Global Health Workforce Alliance. Human resources for health: foundation for universal health coverage and the post2015 development agenda. Report of the Third Global Forum on Human Resources for Health., 2013 November 10–13. Recife, Brazil: WHO; 2014.
46.
go back to reference West M, Dawson J. Employee engagement and NHS performance. London: King’s Fund; 2012. West M, Dawson J. Employee engagement and NHS performance. London: King’s Fund; 2012.
47.
go back to reference World Health Organization. Global strategy on human resources for health: workforce 2030. Geneva: World Health Organisation; 2016. World Health Organization. Global strategy on human resources for health: workforce 2030. Geneva: World Health Organisation; 2016.
48.
go back to reference Figueroa CA, Harrison R, Chauhan A, Meyer L. Priorities and challenges for health leadership and workforce management globally: a rapid review. BMC Health Serv Res. 2019;19(1):239.PubMedPubMedCentralCrossRef Figueroa CA, Harrison R, Chauhan A, Meyer L. Priorities and challenges for health leadership and workforce management globally: a rapid review. BMC Health Serv Res. 2019;19(1):239.PubMedPubMedCentralCrossRef
49.
go back to reference Organisation WH. Working together for health: the world health report 2006: policy briefs. Geneva: World Health Organisation; 2006. Organisation WH. Working together for health: the world health report 2006: policy briefs. Geneva: World Health Organisation; 2006.
50.
go back to reference Organization WH. Global strategy on human resources for health: workforce 2030. Geneva: World Health Organisation; 2016. Organization WH. Global strategy on human resources for health: workforce 2030. Geneva: World Health Organisation; 2016.
51.
go back to reference Reich MR, Javadi D, Ghaffar A. Introduction to the special issue on effective leadership for health systems. Health Syst Reform. 2016;2(3):171–5.PubMedCrossRef Reich MR, Javadi D, Ghaffar A. Introduction to the special issue on effective leadership for health systems. Health Syst Reform. 2016;2(3):171–5.PubMedCrossRef
52.
go back to reference Waddington CED, Travis P, Hawken L, Dovlo D, World Health Organization. Towards better leadership and management in health: report of an international consultation on strengthening leadership and management in low-income countries, 29 January-1 February. Ghana: Accra; 2007. Waddington CED, Travis P, Hawken L, Dovlo D, World Health Organization. Towards better leadership and management in health: report of an international consultation on strengthening leadership and management in low-income countries, 29 January-1 February. Ghana: Accra; 2007.
54.
go back to reference Collaborators GBDCoD. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the global burden of Disease Study 2017. Lancet. 2018;392(10159):1736–88.CrossRef Collaborators GBDCoD. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the global burden of Disease Study 2017. Lancet. 2018;392(10159):1736–88.CrossRef
56.
go back to reference Van Lerberghe W, Matthews Z, Achadi E, Ancona C, Campbell J, Channon A, et al. Country experience with strengthening of health systems and deployment of midwives in countries with high maternal mortality. Lancet. 2014;384(9949):1215–25.PubMedCrossRef Van Lerberghe W, Matthews Z, Achadi E, Ancona C, Campbell J, Channon A, et al. Country experience with strengthening of health systems and deployment of midwives in countries with high maternal mortality. Lancet. 2014;384(9949):1215–25.PubMedCrossRef
57.
go back to reference Petty JK, Vetto JT. Beyond doughnuts: tumor board recommendations influence patient care. J Cancer Educ. 2002;17(2):97–100.PubMed Petty JK, Vetto JT. Beyond doughnuts: tumor board recommendations influence patient care. J Cancer Educ. 2002;17(2):97–100.PubMed
58.
go back to reference Brauer DG, Strand MS, Sanford DE, Kushnir VM, Lim KH, Mullady DK, et al. Utility of a multidisciplinary tumor board in the management of pancreatic and upper gastrointestinal diseases: an observational study. HPB (Oxford). 2017;19(2):133–9.PubMedCrossRef Brauer DG, Strand MS, Sanford DE, Kushnir VM, Lim KH, Mullady DK, et al. Utility of a multidisciplinary tumor board in the management of pancreatic and upper gastrointestinal diseases: an observational study. HPB (Oxford). 2017;19(2):133–9.PubMedCrossRef
59.
go back to reference Pawlik TM, Laheru D, Hruban RH, Coleman J, Wolfgang CL, Campbell K, et al. Evaluating the impact of a single-day multidisciplinary clinic on the management of pancreatic cancer. Ann Surg Oncol. 2008;15(8):2081–8.PubMedPubMedCentralCrossRef Pawlik TM, Laheru D, Hruban RH, Coleman J, Wolfgang CL, Campbell K, et al. Evaluating the impact of a single-day multidisciplinary clinic on the management of pancreatic cancer. Ann Surg Oncol. 2008;15(8):2081–8.PubMedPubMedCentralCrossRef
60.
go back to reference Hoehn RS, Rieser CJ, Winters S, Stitt L, Hogg ME, Bartlett DL, et al. A pancreatic Cancer Multidisciplinary Clinic eliminates socioeconomic disparities in treatment and improves survival. Ann Surg Oncol. 2021;28(5):2438–46.PubMedPubMedCentralCrossRef Hoehn RS, Rieser CJ, Winters S, Stitt L, Hogg ME, Bartlett DL, et al. A pancreatic Cancer Multidisciplinary Clinic eliminates socioeconomic disparities in treatment and improves survival. Ann Surg Oncol. 2021;28(5):2438–46.PubMedPubMedCentralCrossRef
61.
go back to reference Chiang PP, Glance D, Walker J, Walter FM, Emery JD. Implementing a QCancer risk tool into general practice consultations: an exploratory study using simulated consultations with Australian general practitioners. Br J Cancer. 2015;112(Suppl 1):77–83.CrossRef Chiang PP, Glance D, Walker J, Walter FM, Emery JD. Implementing a QCancer risk tool into general practice consultations: an exploratory study using simulated consultations with Australian general practitioners. Br J Cancer. 2015;112(Suppl 1):77–83.CrossRef
62.
go back to reference Pilgrim CHC, Finn N, Stuart E, Philip J, Steel S, Croagh D et al. Changing patterns of care for pancreas cancer in Victoria: the 2022 Pancreas Tumour Summit. Anz J Surg. 2023. Pilgrim CHC, Finn N, Stuart E, Philip J, Steel S, Croagh D et al. Changing patterns of care for pancreas cancer in Victoria: the 2022 Pancreas Tumour Summit. Anz J Surg. 2023.
Metadata
Title
Simulating the healthcare workforce impact and capacity for pancreatic cancer care in Victoria: a model-based analysis
Authors
Lan Gao
Anna Ugalde
Patricia M Livingston
Victoria White
Jennifer J Watts
Hannah Jongebloed
Nikki McCaffrey
David Menzies
Suzanne Robinson
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Health Services Research / Issue 1/2024
Electronic ISSN: 1472-6963
DOI
https://doi.org/10.1186/s12913-024-10722-9

Other articles of this Issue 1/2024

BMC Health Services Research 1/2024 Go to the issue